A Multicenter, Prospective, Randomized, Placebo-Controlled, Double-Blind Study of a Novel Pain Management Device, AT-02, in Patients with Fibromyalgia.

Pain Med · 2020 · PMC7007501 · PMID 31165895

Europe PMC DOI

hedged sentence

0.0859

closest p · 1.7× alpha

0.0859

boldest claim

The sentences

did not reach statistical significanceP = 0.0859so close (0.05 < p ≤ 0.1)

There was a trend toward greater reduction in NRS scores for the AT-02 group (–0.73, 95% confidence interval [CI] = –1.56 to 0.11), but the adjusted difference between the two groups did not reach statistical significance in the ANCOVA analysis ( P = 0.0859).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.